PL438764A1 - Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie - Google Patents

Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie

Info

Publication number
PL438764A1
PL438764A1 PL438764A PL43876421A PL438764A1 PL 438764 A1 PL438764 A1 PL 438764A1 PL 438764 A PL438764 A PL 438764A PL 43876421 A PL43876421 A PL 43876421A PL 438764 A1 PL438764 A1 PL 438764A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
oral suspension
preparation
application
Prior art date
Application number
PL438764A
Other languages
English (en)
Other versions
PL245543B1 (pl
Inventor
Michał Kołodziejczyk
Michał Nachajski
Justyna KOŁODZIEJSKA
Małgorzata GODLEWSKA
Original Assignee
Jezierska Monika Celvet Spółka Cywilna
Marczak Monika Celvet Spółka Cywilna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jezierska Monika Celvet Spółka Cywilna, Marczak Monika Celvet Spółka Cywilna filed Critical Jezierska Monika Celvet Spółka Cywilna
Priority to PL438764A priority Critical patent/PL245543B1/pl
Publication of PL438764A1 publication Critical patent/PL438764A1/pl
Publication of PL245543B1 publication Critical patent/PL245543B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest również niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego zawierająca antybiotyk β-laktamowy, inhibitor β-laktamaz, substancję wypełniającą, substancję żelującą, przeciwutleniacz i substancję poprawiającą smak, charakteryzująca się tym, że substancja wypełniająca jest wybrana z grupy składającej się z triglicerydów kwasów tłuszczowych C8 i C10 i oleju oliwkowego, a substancją żelującą jest krzemionka koloidalna, sposób jej wytwarzania oraz zastosowanie w leczeniu chorób bakteryjnych.
PL438764A 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie PL245543B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL438764A PL245543B1 (pl) 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438764A PL245543B1 (pl) 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie

Publications (2)

Publication Number Publication Date
PL438764A1 true PL438764A1 (pl) 2022-11-14
PL245543B1 PL245543B1 (pl) 2024-08-26

Family

ID=84191751

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438764A PL245543B1 (pl) 2021-01-11 2021-01-11 Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie

Country Status (1)

Country Link
PL (1) PL245543B1 (pl)

Also Published As

Publication number Publication date
PL245543B1 (pl) 2024-08-26

Similar Documents

Publication Publication Date Title
EP4609865A3 (en) Nlrp3 inhibitors
MY203711A (en) Afabicin formulation, method for making the same and uses thereof
AU2024326270A1 (en) Compositions and methods for the treatment of disorders related to frataxin deficiency
PL438764A1 (pl) Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie
AU2024255473A1 (en) Pyrazolopyrimidine derivatives as inhibitors of nlrp3
PL436634A1 (pl) Niewodna kompozycja farmaceutyczna w postaci zawiesiny do podawania doustnego, sposób jej wytwarzania oraz zastosowanie
EP4358934A4 (en) ISOLATED POLYSACCHARIDE COMPOUND AND METHOD OF USE AND MANUFACTURE
CA3255793A1 (en) Angiotensinogen Modulation Compositions and Their Methods of Use
CA3260410A1 (en) CANDLE AND ITS MANUFACTURING PROCESS
CA3263050A1 (en) Compositions for targeted lysosomal degradation and their methods of use
CA3248026A1 (en) Decarboxylated cannabis compositions and methods of making the same
AU2023901246A0 (en) Cleansing formulation and method of manufacture
CA3287651A1 (en) Oral compositions and methods of manufacture
CA3284396A1 (en) Additive and method of manufacturing same
AU2024230123A1 (en) Additive and method of manufacturing same
CA3290230A1 (en) Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods
AU2025902084A0 (en) Formulation and method of manufacture
AU2021900682A0 (en) Pharmaceutical compositions and methods for reducing effects of alcohol consumption
AU2023903226A0 (en) Compositions and methods of making the same
CA3277175A1 (en) Analgesic compositions, method of manufacture and uses thereof
CA3278555A1 (en) Preparation method of pilocarpine and its intermediate compounds
CA3294290A1 (en) Inhibitors of canine janus kinase and uses thereof
HK40120440A (en) Compositions and methods for improved treatment of pompe disease
HK40121460A (en) Pharmaceutical compositions of mosunetuzumab and methods of use
AU2025902002A0 (en) Compositions and methods for the treatment of oesophageal disorders